bearish
Hansoh Pharma IPO: Growth at the Cost of More Pre-IPO Dividends
608 Views20 May 2019 18:49
Hansoh Pharmaceutical (HANSOH HK) claims to be one of the few R&D driven Chinese pharmaceutical companies. According to press reports, Hansoh...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Wanda Sports IPO: A Clank off the Rim?11 Jun 2019
- Last Week in GER Research: ESR Cayman, Hansoh Pharma, China East Education and Tencent10 Jun 2019
- Hansoh Pharma IPO: Valuation Reasonable for the Trade-Offs03 Jun 2019
- Hansoh Pharma IPO Preview: A Decent Story Tarnished by a Huge Pre-IPO Dividend12 Feb 2019
- CStone Pharma IPO Preview: Mixed Prospects of Late-Stage Clinical Drug Candidates29 Jan 2019
x